Under construction – not a live service
Sign in
Taking people in ArgentinaPhase 3

Tests abelacimab against placebo in atrial fibrillation patients unable to take oral blood thinners

Tests abelacimab against placebo in older adults with atrial fibrillation who cannot take blood thinners.

Plain-language title generated from the registry record
Registry title: Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Key facts

Where
Bahía Blanca, Buenos Aires, Ciudad Autónoma Buenos Aires, Ciudad Autónoma de Buenos Aire, Ciudadela, Córdoba, Coronel Suárez, Corrientes, La Plata, Quilmes, Ramos Mejía, Salta, San Luis, San Martin, San Miguel de Tucumán, San Nicolás, Temperley, and Villa María, ArgentinaSee the 35 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for older adults with atrial fibrillation or atrial flutter and a high stroke risk. Their doctor must have judged them unsuitable for blood-thinning tablets, or they refuse them.

Age
65 years or older. Ages 65-74 need a CHA2DS2VASc score of 4 or more. Age 75 and over needs a score of 3 or more.
Sex
All sexes can join.
Disease stage
Atrial fibrillation or atrial flutter shown on an ECG or monitor recording. At least 1 bleeding risk factor is needed, such as severe kidney problems, daily antiplatelet medicine, past bleeding from a critical area, frailty or multiple falls.
Earlier treatment
Unsuitable for oral anticoagulation, or unwilling to take it. Also unsuitable for a left atrial appendage closure device, or unwilling to have one, or no approved device is available. These decisions were made before and independent of the study. No vitamin K antagonist or direct oral anticoagulant in the last 60 days.

Main reasons for not taking part

  • AF caused by a short-term reversible cause, such as cardiac surgery or untreated hyperthyroidism
  • Intracranial or intraocular bleed in the last 3 months, or any past spontaneous brain bleed without blood-thinning treatment
  • Stroke in the last 14 days or TIA in the last 3 days
  • Mechanical heart valve, or valve disease likely to need mechanical valve replacement
  • On dialysis, or dialysis planned within 6 months

Read by machine on 12 November 2026.

Where in Argentina

  • Bahía Blanca, Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Buenos Aires, Buenos Aires F.D.Hospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Buenos Aires, Buenos Aires F.D.Hospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Ciudad Autónoma Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Ciudad Autónoma de Buenos AireHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Ciudad Autónoma de Buenos AireHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Ciudadela, Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Córdoba, Córdoba ProvinceHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CórdobaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Coronel SuárezHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • CorrientesHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • La Plata, Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • La PlataHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • QuilmesHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Ramos MejíaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • SaltaHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Salta, Salta ProvinceHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San LuisHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San MartinHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San Miguel de TucumánHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San Miguel de Tucumán, Tucumán ProvinceHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San Miguel de TucumánHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San Miguel de TucumánHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • San NicolásHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Temperley, Buenos AiresHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people
  • Villa María, Córdoba ProvinceHospital not named in the registryContact: Anthos Therapeutics a Novartis CompanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Anthos Therapeutics, Inc.
Trial code
NCT05712200EU 2023-503224-66-00
Record updated
13 July 2026
Original description
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.Read full original descriptionShow less

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Inclusion: Patient is able to understand and has provided written informed consent to participate in the trial; Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording); Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3; Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study; At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls; Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study.

Exclusion: Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF; Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment; Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization; AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use); Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study; Patients on dialysis at screening or who are planned to start dialysis within 6 months; Other protocol defined Inclusion/Exclusion criteria may apply.

ClinicalTrials.gov NCT05712200 · EU CTIS 2023-503224-66-00